Bicara Therapeutics stock rating reiterated as Buy by TD Cowen

TD Cowen reiterated its Buy rating on Bicara Therapeutics (BCAX), citing the recent $8 billion Merus acquisition by Genmab as strong validation for Bicara's EGFR bispecific antibody platform and suggesting a significant valuation gap. This positive outlook is echoed by other firms like Jones Trading, H.C. Wainwright, and Piper Sandler, which have initiated or maintained Buy/Overweight ratings with price targets up to $40, driven by confidence in Bicara's Phase III clinical trial design and the potential of its treatments, despite the stock's recent 32% surge.

Analysis

Bicara Therapeutics (BCAX) is experiencing a wave of positive analyst sentiment, anchored by TD Cowen's reiterated 'Buy' rating. The primary catalyst is the recent $8 billion acquisition of Merus by Genmab, which is seen as a significant validation for the emerging class of EGFR bispecific antibodies, a core area for Bicara. Analysts at TD Cowen highlight a "far too great" valuation gap between Bicara and Merus, suggesting substantial upside potential from its current trading price of $14.07, even after a 32% surge in the past week. This bullish outlook is broadly shared, with Jones Trading initiating coverage with a 'Buy' rating and a $22 price target, and Piper Sandler assigning an 'Overweight' rating with a $36 target. H.C. Wainwright also maintains a 'Buy' rating, setting a high price target of $40, although it noted an increase in long-term operating expense estimates. Confidence in the company's fundamentals is supported by TD Cowen's belief in the durability and high probability of success for Bicara's Phase III clinical trial design for its head and neck cancer treatment.

Key Decisions for Investors

• Given the strong analyst consensus and the M&A validation from the Merus acquisition, investors may view the perceived valuation gap as an opportunity to build or add to a position in BCAX, as multiple price targets suggest significant upside remains despite the recent rally.
• Investors should closely monitor progress and data from Bicara's Phase III clinical trial, as its success is a cornerstone of the bullish thesis and a key potential catalyst for closing the valuation gap.
• While the M&A context is compelling, it is prudent to factor in the inherent volatility of a clinical-stage biotech, highlighted by the wide analyst price target range of $8 to $48 and H.C. Wainwright's note on rising long-term operating expenses.